Latest filings (excl ownership)
PRE 14A
Preliminary proxy
16 Apr 24
S-3
Shelf registration
29 Mar 24
S-3
Shelf registration
29 Mar 24
424B5
Prospectus supplement for primary offering
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update
28 Mar 24
8-K
Daré Bioscience Announces Executive Team and Board of Directors Changes
26 Jan 24
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
19 Jan 24
8-K
Regulation FD Disclosure
8 Jan 24
D
$4.16 mm in options / securities to be acquired, sold $1.73 mm, 1 investor
26 Dec 23
8-K
Daré Bioscience Secures $12 million in Royalty-backed Investment Structure $5 million at closing and up to $7 million of additional committed funding
26 Dec 23
8-K
Daré Bioscience Announces Positive Topline Pharmacokinetic and Exploratory Efficacy Results from the DARE-PDM1 Phase 1 Clinical Study
20 Dec 23
8-K
Changes in Registrant's Certifying Accountant
9 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Daré Bioscience Reports Third Quarter 2023 Financial Results and Provides Company Update
9 Nov 23
8-K
Regulation FD Disclosure
1 Nov 23
8-K
Regulation FD Disclosure
16 Oct 23
8-K
Regulation FD Disclosure
11 Sep 23
424B5
Prospectus supplement for primary offering
30 Aug 23
8-K
Daré Bioscience Announces $7.0 Million
30 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Daré Bioscience Reports Second Quarter 2023 Financial Results and Provides a Company Update
10 Aug 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
21 Jul 23
8-K
Daré to receive $1 million in July 2023 and $181.8 million in potential milestone payments from Organon under XACIATO global license agreement
5 Jul 23
8-K
Submission of Matters to a Vote of Security Holders
22 Jun 23
8-K
Regulation FD Disclosure
5 Jun 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Results of Operations and Financial Condition
11 May 23
ARS
2022 FY
Annual report to shareholders
1 May 23
DEFA14A
Additional proxy soliciting materials
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
424B5
Prospectus supplement for primary offering
31 Mar 23
8-K
Entry into a Material Definitive Agreement
31 Mar 23
10-K
2022 FY
Annual report
30 Mar 23
8-K
Daré Bioscience Reports Full Year 2022 Financial Results and Provides a Company Update
30 Mar 23
8-K
Other Events
13 Mar 23
8-K
Other Events
6 Feb 23
8-K
Amendments to Articles of Incorporation or Bylaws
27 Jan 23
8-K
Other Events
25 Jan 23
8-K
Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause
9 Jan 23
Latest ownership filings
4
John A Fair
14 Mar 24
4
SABRINA MARTUCCI JOHNSON
14 Mar 24
4
MarDee Haring-Layton
14 Mar 24
3
MarDee Haring-Layton
29 Jan 24
4
Cheryl R Blanchard
21 Jun 23
4
Jessica D. Grossman
21 Jun 23
4
Robin Joan Steele
21 Jun 23
4
Sophia Nnenna Ononye-Onyia
21 Jun 23
4
Susan L. Kelley
21 Jun 23
4
WILLIAM H RASTETTER
21 Jun 23
4
Gregory W Matz
21 Jun 23
4
SABRINA MARTUCCI JOHNSON
26 Jan 23
4
Lisa Walters-Hoffert
26 Jan 23
4
John A Fair
26 Jan 23
4
WILLIAM H RASTETTER
24 Jun 22
4
Robin Joan Steele
24 Jun 22
4
Gregory W Matz
24 Jun 22
4
Sophia Nnenna Ononye-Onyia
24 Jun 22
4
Jessica D. Grossman
24 Jun 22
4
Cheryl R Blanchard
24 Jun 22
4
Susan L. Kelley
24 Jun 22
SC 13G/A
VANGUARD GROUP INC
9 Feb 22
SC 13G/A
VANGUARD INDEX FUNDS
9 Feb 22
4
John A Fair
28 Jan 22
4
SABRINA MARTUCCI JOHNSON
28 Jan 22
4
Lisa Walters-Hoffert
28 Jan 22
4
Robin Joan Steele
24 Jun 21
4
Gregory W Matz
24 Jun 21
4
Susan L. Kelley
24 Jun 21
4
Cheryl R Blanchard
24 Jun 21
4
Jessica D. Grossman
24 Jun 21
4
WILLIAM H RASTETTER
24 Jun 21
4
Sophia Nnenna Ononye-Onyia
20 Apr 21
3
Sophia Nnenna Ononye-Onyia
20 Apr 21
SC 13G/A
POLARIS VENTURE PARTNERS III LP
12 Feb 21
SC 13G
VANGUARD GROUP INC
10 Feb 21
SC 13G/A
Hudson Bay Capital Management LP
9 Feb 21
SC 13G
VANGUARD INDEX FUNDS
8 Feb 21
4
John A Fair
28 Jan 21
4
Lisa Walters-Hoffert
28 Jan 21